BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease

Neuroscience Letters

Volumn 561, Issue , 2014, Pages 86-90

  Białecka, Monika ^a   Kurzawski, Mateusz ^a   Roszmann, Anna ^b,c   Robowski, Piotr ^b,c   Sitek, Emilia J ^b,c   Honczarenko, Krystyna ^a   Mak, Monika ^a   Deptuła Jarosz, Monika ^d   Gołab Janowska, Monika ^a   Droździk, Marek ^a   Sławek, Jarosław ^b,c  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c ST ADALBERT HOSPITAL   (Poland)

^d Marie Curie Regional Hospital   (Poland)

Author keywords

BDNF; Dementia; Genetic polymorphism; Parkinson's disease

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; METHIONINE; VALINE;

ADULT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HOEHN AND YAHR SCALE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MOTOR PERFORMANCE; NEUROLOGIC EXAMINATION; ONSET AGE; PARKINSON DISEASE; PATIENT ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SCHWAB ENGLAND SCALE; UNIFIED PARKINSON DISEASE RATING SCALE;

BDNF; DEMENTIA; GENETIC POLYMORPHISM; PARKINSON'S DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BRAIN-DERIVED NEUROTROPHIC FACTOR; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMORPHISM, GENETIC;

EID: 84892490837     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.12.051     Document Type: Article

References (38)

1. Bath K.G., Lee F.S. Variant BDNF (Val66Met) impact on brain structure and function. Cogn. Affect. Behav. Neurosci. 2006, 6:79-85.
2. Barone P., Aarsland D., Burn D., Emre M., Kulisevsky J., Weintraub D. Cognitive impairment in nondemented Parkinson's disease. Mov. Disord. 2011, 26:2483-2495.
3. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
4. Diniz B.S., Teixeira A.L. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromol. Med. 2011, 13:217-222.
5. Dujardin K., Leentjens A.F., Langlois C., Moonen A.J., Duits A.A., Carette A.S., Duhamel A. The spectrum of cognitive disorders in Parkinson's disease: a data-driven approach. Mov. Disord. 2013, 28:183-189.
6. Emre M., Aarsland D., Brown P., Burn D.J., Duyckaerts C., Mizuno Y., Broe G.A., Cummings J., Dickson D.W., Gauthier S., Goldman J., Goetz C., Korczyn A., Lees A., Levy R., Litvan I., McKeith I., Olanow W.W., Poewe W., Quinn N., Sampaio C., Tolosa E., Dubois B. Clinical diagnostic criteria in Parkinson's disease associated with dementia. Mov. Disord. 2007, 12:1689-1707.
7. Folstein M.F., Folstein S.E., McHugh P.R. Minimental state: a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
8. Foltynie T.T., Cheeran B., Williams-Gray C.H., Edwards M.J., Schneider S.A., Weinberger D., Rothwell J.C., Barker R.A., Bhatia K.P.K.P. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2009, 80:141-144.
9. Gao L., Díaz-Corrales F.J., Carrillo F., Díaz-Martín J., Caceres-Redondo M.T., Carballo M., Palomino A., López-Barneo J., Mir P. Brain-derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease. Acta Neurol. Scand. 2010, 122:41-45.
10. Guerini F.R., Beghi E., Riboldazzi G., Zangaglia R., Pianezzola C., Bono G., Casali C., Di Lorenzo C., Agliardi C., Nappi G., Clerici M., Martignoni E. BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease. Eur. J. Neurol. 2009, 16:1240-1245.
11. Hall T.O., Wan J.Y., Mata I.F., Kerr K.S., Snapinn K.W., Samii A., Roberts J.W., Agarwal P., Zabetian C.P., Edwards K.L. Risk prediction for complex diseases: application to Parkinson disease. Genet. Med. 2013, 15:361-367.
12. Halliday G.N., McCann H. The progression of pathology in Parkinson's disease. Ann. N. Y. Acad. Sci. 2010, 1184:188-195.
13. Håkansson A., Melke J., Westberg L., Shahabi H.N., Buervenich S., Carmine A., Klingborg K., Grundell M.B., Schulhof B., Holmberg B., Ahlberg J., Eriksson E., Sydow O., Olson L., Johnels B.H. Nissbrandt Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population. Ann. Neurol. 2003, 53:823.
14. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1967, 17:427-442.
15. Hong C.J., Liu H.C., Liu T.Y., Lin C.H., Cheng C.Y., Tsai S.J. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset. Neurosci. Lett. 2003, 353:75-77.
16. Hughes A.J., Daniel S.E., Blankson S.E., Lees A.L. A clinicopathological study of 100 cases of Parkinson's disease. Arch. Neurol. 1993, 50:140-148.
17. Jokinen P., Bruck A., Aalto S., Forsback S., Parkkola R., Rinne J.O. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat. Disord. 2009, 15:88-93.
18. Karakasis C., Kalinderi K., Katsarou Z., Fidani L., Bostantjopoulou S. Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with Parkinson's disease in a Greek population. Clin. Neurosci. 2011, 18:1744-1745.
19. Karamohamed S., Latourelle J.C., Racette B.A., Perlmutter J.S., Wooten G.F., Lew M., Klein C., Shill H., Golbe L.I., Mark M.H., Guttman M., Nicholson G., Wilk J.B., Saint-Hilaire M., DeStefano A.L., Prakash R., Tobin S., Williamson J., Suchowersky O., Labell N., Growdon B.N., Singer C., Watts R., Goldwurm S., Pezzoli G., Baker K.B., Giroux M.L., Pramstaller P.P., Burn D.J., Chinnery P., Sherman S., Vieregge P., Litvan I., Gusella J.F., Myers R.H., Parsian A. BDNF genetic variants are associated with onset age of familial Parkinson disease: gene PD study. Neurology 2005, 65:1823-1825.
20. Kehagia A.A., Barker R.A., Robbins T.W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol. 2010, 9:1200-1213.
21. Kim J.S., Oh Y.S., Lee K.S., Kim Y.I., Yang D.W., Goldstein D.S. Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 2012, 79:1323-1331.
22. Leverenz J.B., Watson G.S., Shofer J., Zabetian C.P., Zhang J., Montine T.J. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat. Disord. 2011, 17:61-64.
23. Levy G., Schupf N., Tang M.X., Cote L.J., Louis E.D., Mejia H., Stern Y., Marder K. Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann. Neurol. 2002, 51:722-729.
24. Lu B., Nagappan G., Guan X., Nathan P.J., Wren P. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci. 2013, 14:401-416.
25. Masaki T., Matsushita S., Arai H., Takeda A., Itoyama Y., Mochizuki H., Kamakura K., Ohara S., Higuchi S. Association between a polymorphism of brain-derived neurotrophic factor gene and sporadic Parkinson's disease. Ann. Neurol. 2003, 54:276-277.
26. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I.I., Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann. Neurol. 2002, 51:133-136.
27. Nagahara A.H., Tuszynski M.H. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat. Rev. Drug Discov. 2011, 10:209-219.
28. Papapetropoulos S., Adi N., Ellul J., Argyriou A.A., Chroni E. A prospective study of familial versus sporadic Parkinson's disease. Neurodegener. Dis. 2007, 4:424-427.
29. Parsian A., Sinha R., Racette B., Zhao J.H., Perlmutter J.S.J.S. Association of a variation in the promoter region of the brain-derived neurotrophic factor gene with familial Parkinson's disease. Parkinsonism Relat. Disord. 2004, 10:213-219.
30. Peng S., Wuu J., Mufson E.J., Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 2005, 93:1412-1421.
31. Riedel O., Klotsche J., Spottke A., Deuschl G., Förstl H., Henn F., Heuser I., Oertel W., Reichmann H., Riederer P., Trenkwalder C., Dodel R., Wittchen H.U. Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German study on epidemiology of Parkinson's disease with dementia (GEPAD). J. Neurol. 2008, 255:255-264.
32. Slawek J., Roszman A., Robowski P., Dubaniewicz M., Sitek E.J., Honczarenko K., Gorzkowska A., Budrewicz S., Mak M., Gołab-Janowska K., Koziorowska-Gawron E., Drozdzik M., Kurzawski M., Bandurski T., Bialecka M. The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors. Neurodegener. Dis. 2013, 12(1):1-12.
33. Schulz-Schaeffer W.J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol. 2010, 120:131-143.
34. Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov. Disord. 2013, 28:14-23.
35. Teixeira A.L., Barbosa I.G., Diniz B.S., Kummer A. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark. Med. 2010, 4:871-887.
36. Zintzaras E., Hadjigeorgiou G.M. The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson's disease: meta-analysis. J. Hum. Genet. 2005, 50:560-566.
37. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.
38. Yang F., Je H.S., Ji Y., Nagappan G., Hempstead B., Lu B. Pro-BDNF-induced synaptic depression and retraction at developing neuromuscular synapses. J. Cell Biol. 2009, 185:727-741.